ghrelin receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
Neil Alan Dickson, MBE. Co-Founder, The Brain Tumour Charity. For services to People with Brain Tumours. Andrew James Dixon. Founding Trustee, Woodhaven Trust and Fairer Share and Founder, Arc InterCapital. For services to Prisoners and Ex-Offenders, to Property Tax Reform and to Entrepreneurship. Josephine Naomi Clare Dobrin. Co-Founder and Executive Chair, Creative Access. For services to the Creative Industries. Jonathan Donaghy. Deputy Director, Customs, HM Treasury. For Public Service. Amy Louise Doncaster. Deputy Director, Strategy and Future Design, Department for Work and Pensions. For Public Service. Terence Anthony Donnelly. Executive Chair, Donnelly Motor Group and Director, Taxi and Bus Conversions Ltd. For services to the Motor Industry in Northern Ireland. Professor Carol Ann Doyle. Lately Head of School for Nursing and Midwifery Education, Birmingham City University. For services to Nurse Education. Rachael Louise Doyle (Rachael Mills). Director, SE2 and Chirpy Heat. For services to Energy Efficiency and to Diversity and Inclusion. Philip Stephen Dudderidge. Co-Founder and Chair, Focusrite plc. For services to Business and to the Music Industry. Andrew Grant Duncan, DL. For services to the community in Worcestershire. Michael George Eakin. Chief Executive, Royal Liverpool Philharmonic. For services to Music and to the community in Liverpool, Merseyside. Catherine Louise Edwards. Lately Clinical Programmes Director, National Specialised Commissioning, NHS England. For services to the NHS. Emrys Shaun Elias.
The life science training pathway for clinical scientists follows a similar pathway to that undertaken by medically qualified specialist registrars in pathology. Clinical scientists are therefore the only discipline of non-medical healthcare professionals examined by a Medical Royal College. Clinical scientists who attain both part 1 examination certification and part 2 certification are awarded Fellowship of the Royal College of Pathologists (FRCPath) and are deemed to have the knowledge and expertise expected of a consultant level scientist. Consultant clinical scientist posts generally require candidates to have completed FRCPath qualification to be eligible. All clinical scientists regardless of seniority or specialisation may have other responsibilities including academic appointments, responsibilities as clinical lead for a pathology service, or may have wider hospital responsibilities such as directorship of Infection Prevention and Control, or responsibility for the hospital's Research and Development strategy. Junior clinical scientists may become involved in academic research, working towards a Ph.D. or DClinSci.
Flupentixol (INN), also known as flupenthixol (former BAN), marketed under brand names such as Depixol and Fluanxol is a typical antipsychotic drug of the thioxanthene class. It was introduced in 1965 by Lundbeck. In addition to single drug preparations, it is also available as flupentixol/melitracen—a combination product containing both melitracen (a tricyclic antidepressant) and flupentixol (marketed as Deanxit). It is approved for use in the UK, Australia, Canada, Russian Federation, South Africa, New Zealand, Philippines, Iran, Germany, among others. Flupentixol is not approved for use in the United States.
=== DEA classification === Vicoprofen was initially scheduled as a schedule III drug, but was later reclassified to a schedule II drug based on the DEA reclassification of products containing hydrocodone, effective October 2014.
=== Sensory transduction === Pacinian corpuscles sense stimuli due to the deformation of their lamellae in the capsule and inner core, which in turn press on the membrane (axolemma) of the sensory neuron and causes it to bend or stretch. The external stimulus (deformation of or force on the external surface of the capsule) reaches axolemma of the terminal neurite through a complex mechanical filtration process. The internal lamellar spacing, number of lamella present in the capsule and the biomechanical properties of lamellae and the interlamellar fluid governs the characteristics of this mechanical filter acting on the external stimulus. When the axolemma are deformed by the filtered stumulus, due to either application or release of the external stimulus, a generator or receptor potential is created as it physically deforms the plasma membrane of axon terminal, making it "leak" different cations through mechanosensitive channels which initiates the receptor potential. This initial receptor potential is potentiated by voltage-activated ion channels present in the inner-core of the corpuscle. Finally, the receptor potential is modulated to neural spikes or action potential with the help of opening of sodium ion channels present at the first Ranvier's Node of the axon. Due to generation of receptor potential in the receptive area of the neurite (especially near the heminode or half-node of the axon) the potential at the first Ranvier's node can reach certain threshold, triggering nerve impulses or action potentials at the first node of Ranvier.
Sources: en.wikipedia.org
A nerve fascicle is a bundle of nerve fibers belonging to a nerve in the peripheral nervous system. A nerve fascicle is also called a fasciculus. In the central nervous system, the analogous structures are known as nerve tracts.
==== Functional linkers as catalytic sites ==== Functional linkers can be also utilized as catalytic sites. A 3D MOF {[Cd(4-btapa)2(NO3)2] • 6H2O • 2dmf} (H34-btapa= 1,3,5-benzene tricarboxylic acid tris [N-(4-pyridyl)amide], dmf = N,N-dimethylformamide) constructed by tridentate amide linkers and cadmium salt catalyzes the Knoevenagel condensation reaction. The pyridine groups on the ligand 4-BTAPA act as ligands binding to the octahedral cadmium centers, while the amide groups can provide the functionality for interaction with the incoming substrates. Specifically, the −NH moiety of the amide group can act as electron acceptor whereas the C=O group can act as electron donor to activate organic substrates for subsequent reactions. Ferey et al. reported a robust and porous MOF [Cr3(μ3-O)F(H2O)2(BDC)3] (BDC: benzene-1,4-dicarboxylate) where instead of directly using the unsaturated Cr(III) centers as catalytic sites, the authors grafted ethylenediamine (ed) onto the Cr(III) sites. The uncoordinated ends of ed can act as base catalytic sites. ed-grafted MOF was investigated for Knoevenagel condensation reactions. A significant increase in conversion was observed for ed-grafted MOF compared to untreated framework (98% vs. 36%). Another example of linker modification to generate catalytic site is iodo-functionalized well-known Al-based MOFs (MIL-53 and DUT-5) and Zr-based MOFs (UiO-66 and UiO-67) for the catalytic oxidation of diols.
In Cuba, there was also a nascent "Cuban identity," based in free thought, secular social institutions, and ideological liberalism. Colon Freemasonry and Cuban Freemasonry moved closer together ideologically, but could still not agree on the core tenets of Freemasonry and the ideology of Cuban independence. Over the next several years, the Grand Lodge of the Island of Cuba surpassed Colon Freemasonry. Almeida y González wrote an entirely new Masonic Code. He wrote literature and books about Freemasonry, including El Consultor Del Masón (English: The Mason's Consultant) and Jurisprudencia Masónica (English: Masonic Jurisprudence). He also reproduced many of the works of GOCA and Vicente Antonio de Castro. These works were widely distributed within Latin American Freemasonry. The Grand Lodge of the Island of Cuba was the first Cuban body in history to spread into Spain and charter its own Lodges on the mainland.
In relation to the significance of the event(s) on career choice, when merging the categories ‘probably chosen career regardless’ with ‘possibly chosen career regardless’, and ‘unlikely chosen career regardless’ with ‘not considered career otherwise’, there is a slight majority in relation to the former. There are no significant differences in relation to demographic factors. In relation to whether one or more psychologically wounding experiences led to the choice of a career as a therapist, there is a significant difference within designation, gender, grouping gender and ethnicity, and, grouping gender and age. There are no significant differences within approach, ethnicity or age. The majority of the wounds were caused by events experienced directly by the respondents (65%) as opposed to indirectly or both. Within demographic factors, the causes of the wounding experiences leading to career choice are not statistically significant. The exact causes of the wounds vary enormously. The main categories are abuse, family life as a child, mental ill-health (own), social, family life as an adult, bereavement, mental ill-health (others), life-threatening, physical ill-health (others), physical ill-health (own), and, other. There are many implications for the future of the therapeutic world, focusing mainly on supervision and training. The largest prevalence study on lived experience within the mental health field by Victor et al.
Alongside continued research defensive countermeasures there has been a proliferation of nuclear weapons around the world. Many nations have acquired technology required to produce nuclear weapons since the end of the Cold War. India tested its first nuclear weapon with Operation Smiling Buddha in 1974. It was followed by Pakistan's nuclear program acquiring centrifuges capable of enriching uranium in the 80's and in 1998 was able to conduct several underground tests. Today the United States, Russia, the United Kingdom, France, and China all possess nuclear weapons and have signed the Nuclear Non-Proliferation Treaty in an attempt to curb the spread of nuclear weapons. India, Pakistan, Israel and North Korea are also in possession of nuclear technology but have not signed the Nuclear Non-Proliferation Treaty. The Cold War brought with it increased research into radio technology as well as nuclear weapons. The success of Sputnik 1 lead to an increase funding for radio telescopes such as Jodrell Bank Observatory for use in tracking Sputnik and possible nuclear launches by the Soviet Union. Jodrell Bank and other observatories like it have since been used to track space probes as well as investigate quasars, pulsars, and meteoroids. Satellites such as the Vela that were originally launched to detect nuclear detonation following the Partial Nuclear Test Ban Treaty have been used since then to discover and further investigate gamma-ray bursts. A new space race began in the 2020s, largely between the United States' Artemis Program and China's Lunar Exploration Program.
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.